Nakshbandi, Gizal
Moor, Catharina C.
Antoniou, Katerina
Cottin, Vincent
Hoffmann-Vold, Anna-Maria
Koemans, Edwin A.
Kreuter, Michael
Molyneaux, Philip L.
Wuyts, Wim A.
Wijsenbeek, Marlies S.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Study protocol of an international patient-led registry in patients with pulmonary fibrosis using online home monitoring: I-FILE
https://doi.org/10.1186/s12890-023-02336-4
Article History
Received: 10 November 2022
Accepted: 19 January 2023
First Online: 2 February 2023
Declarations
:
: The study will be performed in accordance with the Declaration of Helsinki. The medical ethical committee of the Erasmus Medical Center has approved the trial with the protocol reference number MEC-2020-0029. Approval from the Medical Ethics Committee of all participating sites will also be obtained. Written informed consent will be obtained from the participants.
: Not applicable.
: GN: Financial grant from Boehringer Ingelheim paid to institution. CM: Financial grant from Boehringer Ingelheim, Astra—Zeneca, Daiichi-Sankyo paid to institution. Payments for presentations/lectures from Boehringer-Ingelheim and Hoffman—la Roche paid to institution. KA: Consulting fees from Boehringer Ingelheim, Hoffman—la Roche and GSK. Payments for presentations/lectures from Boehringer Ingelheim, Hoffman—la Roche, Chiesi, Menarini, GSK, AstraZeneca. VC: Financial grant from Boehringer Ingelheim paid to institution. Consulting fees from Astra Zeneca, Boehringer Ingelheim, Celgene/BMS, CSL Behring, GSK, Pliant, Pure Tech, RedX, Hoffman—la Roche, Sanofi, Shionogi, United Therapeutics/Ferrer. Payments for presentations/lectures from Boehringer Ingelheim and Hoffman—La Roche. Support for attending meetings from Boehringer Ingelheim and Hoffman—La Roche. Participation on data and safety monitoring board of Galapagos and Galecto. Leadership role in Fibrogen adjudication committee. AV: Grants from ARXX therapeutics, Boehringer Ingelheim, Hoffman—la Roche, Bayer, Merck Sharp&Dohme, Lilly and Medscape. Consulting fees from ARXX therapeutics, Boehringer Ingelheim, Roche, Merck Sharp&Dohme, Lilly, Medscape, Genentech. Payments for presentations/lectures from ARXX therapeutics, Boehringer Ingelheim, Roche, Bayer, Merck Sharp&Dohme, Lilly and Medscape. Support for attending meetings from Boehringer Ingelheim and Janssen. Leadership role in EULAR convenor for ERS/EULAR CTD-ILD guideline, EULAR quality of care committee, PH Nordic group. MK: Financial grant from Boehringer Ingelheim and Hoffman—la Roche. Consulting fees from Boehringer Ingelheim and Hoffman—la Roche. Payments for presentations/lectures from Boehringer Ingelheim and Hoffman—la Roche. Leadership role in ERS and DGP. PM: Financial grant from Astra Zeneca and Action for Pulmonary Fibrosis payed to institution. Advisory board fees from Hoffman—la Roche, Boehringer Ingelheim, Qureight, Trevi, AstraZeneca. Speakers fees from Astra Zeneca, Boehringer Ingelheim, Hoffman—La Roche. WW: Financial grant from Hoffman—la Roche, Boehringer Ingelheim, Galapagos paid to institution. Consulting fees from Hoffman—la Roche, Boehringer Ingelheim, Galpagos paid to institution. Payments for presentations/lectures from Boehringer Ingelheim paid to institution. Participation on Advisory board by Boehringer Ingelheim, Galapagos, Hoffman—La–Roche paid to institution. MW: Financial grant from Boehringer Ingelheim, Hoffman—La Roche, The Netherlands Organization for Health Research and Development; The Dutch Lung Foundation; The Dutch Pulmonary Fibrosis, all paid to institution. Consulting fees from Bristol Myers Squibb, Boehringer Ingelheim, Galapagos, Galecto, Hoffman la Roche, Horizon therapeutics, Kinevant Sciences, Molecure, Nerre Therapeutics, Novartis, PureTech Health, and Respivant, all paid to institution. Support for attending meeting from Boehringer Ingelheim, Hoffman la Roche, Galapagos. Participation on advisory board from Savara, Galapagos, all paid to institution. Leadership role as Chair of the Idiopathic Interstitial Pneumonia group of the European Respiratory Society, Member of the board of the Netherlands Respiratory Society, Member of the scientific advisory board of the European Idiopathic Pulmonary Fibrosis and related disorders federation, Chair of the educational committee of the European Reference Network for rare Lung Diseases, Advisory board of the Dutch Lung fibrosis and Sarcoidosis patient associations.